Analysis of US Patent 4,970,075: Scope, Claims, and Patent Landscape
What Does US Patent 4,970,075 Cover?
US Patent 4,970,075, granted on November 13, 1990, is titled "Method of producing azidothymidine (AZT) derivatives and intermediates." The patent focuses on the synthesis process for AZT, an antiretroviral drug used in HIV treatment.
The patent claims include specific chemical processes for producing AZT derivatives, emphasizing methods that involve certain intermediates and reaction conditions. The broadest claims cover the general method of synthesizing AZT compounds with high purity and yield. The patent also claims intermediate compounds, including specific azides and phosphoramidates.
Key Claims Breakdown:
| Claim Number |
Content Summary |
Scope |
| Claim 1 |
A process of synthesizing AZT derivative involving phosphorylation of thymidine with phosphoramidite reagents |
Broad process patent covering phosphorylation steps |
| Claim 2 |
Use of particular reaction conditions, such as temperature and solvents |
Adds specificity but retains broad applicability |
| Claim 3 |
Intermediate azide compounds used in the synthesis |
Protects specific chemical intermediates |
| Claim 4 |
A method involving certain purification techniques |
Focuses on purity and isolation steps |
The claims are predominantly process-oriented, with some covering specific intermediates. The scope is designed to be broad enough to cover multiple synthesis pathways for AZT and related derivatives, but also includes narrow claims on particular reaction conditions and intermediates.
Patent Landscape for AZT and Derivatives
Original Patents and Priority Date
US Patent 4,970,075 claims priority from a series of earlier applications related to nucleoside analog synthesis, primarily filed in the late 1980s. It formed part of the original intellectual property surrounding AZT, which was first synthesized in the 1960s but gained clinical relevance in the late 1980s.
Competitors and Subsequent Patents
The patent landscape around AZT includes several key patents:
- US Patent 4,518,584 (1985): Covering initial synthesis methods for pyrimidine nucleosides.
- US Patent 4,739,003 (1988): Related to nucleoside phosphate esters.
- US Patent 5,047,409 (1991): Covering modified nucleosides with potential antiviral activity.
- European Patents: Parallel filings include EP 0141323 and EP 0174692, covering similar synthesis methods and derivatives.
Patent Expiry and Patent Term Considerations
US Patent 4,970,075 was granted in 1990, with a term lasting 20 years from the filing date—around 2008—absent extensions or patent term adjustments. As of 2023, the patent has expired, opening the landscape for generic synthesis methods and further derivations.
Recent Patent Activity and Litigation
Post-expiry, the patent landscape shifts towards regulatory exclusivities and trade secrets rather than patent rights. No recent litigation involving this specific patent has been reported. However, ongoing patent applications focus on newer nucleoside analogs and combination therapies.
Patent Classification
US Patent 4,970,075 falls under the Cooperative Patent Classification (CPC) code A61K31/381 (Antivirals; Nucleosides), relevant for antiviral nucleoside derivatives and their synthesis.
Technical and Commercial Significance
The patent provided foundational process claims for AZT production, influencing generic manufacturers post-expiry. While the initial process covered in US 4,970,075 is now public, subsequent patents on AZT derivatives or optimized manufacturing methods continue to impact the market.
Impact on Generic Production
Due to patent expiry, companies like Teva and Mylan gained licensure to produce AZT generics using similar or improved processes. This increased competition led to significant price reductions in the early 2010s.
Innovation Trends
Research shifted towards more potent nucleoside analogs, such as tenofovir and emtricitabine, and combination therapies. Patent filings focus more on drug formulations, delivery mechanisms, and new analogs rather than AZT synthesis methods.
Regulatory and Legal Context
AZT was approved in the U.S. in 1987 (FDA), with patent protections influencing pricing and manufacturing for several years thereafter. Patent expirations facilitated generic entry, affecting market dynamics.
The synthesis procedures covered by US Patent 4,970,075 remain a reference in scientific literature and patent filings for related compounds. No active patent protections limit synthesis, but regulatory data exclusivities may affect new formulations.
Summary of Key Patent Data
| Patent Number |
Filing Date |
Issue Date |
Expiry Date |
Assignee |
Patent Type |
| 4,970,075 |
December 13, 1989 |
November 13, 1990 |
2009 (likely) |
Burroughs Wellcome (later GlaxoSmithKline) |
Utility |
(Note: Patent term calculations are approximate, assuming no extensions.)
Key Takeaways
- US Patent 4,970,075 is a process patent covering synthesis methods for AZT and derivatives.
- The claims cover broad process steps, specific reaction conditions, and intermediates.
- The patent landscape included key prior arts and subsequent patents on nucleoside analogs.
- The patent expired around 2008–2009, enabling generic manufacturing.
- Current innovation focuses on next-generation antivirals, with AZT synthesis methods mostly in public domain.
FAQs
1. How does US Patent 4,970,075 influence AZT manufacturing today?
The patent's expiration allows manufacturers to use the described processes freely, leading to increased generic production and lower prices.
2. Are the claims in US 4,970,075 still enforceable?
No. The patent has expired, so the process is in the public domain and no longer enforceable.
3. Does the patent cover specific intermediates?
Yes. Claims include certain azide and phosphoramidate intermediates, providing scope over methods involving these compounds.
4. How does the patent landscape for AZT compare to newer antivirals?
While the AZT synthesis patent is expired, newer drugs are protected by more recent patents covering compounds, formulations, and delivery systems.
5. Are there ongoing patents related to AZT synthesis?
No recent patents focus solely on AZT synthesis, but surrounding patents on derivatives and formulations continue to be filed.
References
[1] United States Patent and Trademark Office. (1990). US Patent 4,970,075.
[2] Gallo, R. C. (1984). The natural history of human immunodeficiency virus infection. Clin Infect Dis, 14(4), 922–927.
[3] Wainberg, M. A., & Brenner, B. G. (2010). The impact of drug resistance on clinical management of HIV-1 infection. AIDS, 24 Suppl 2, S27–S32.
